|Saxagliptin||Dipeptidyl peptidase-4 inhibitor|
|AHFS/Drugs.com||Professional Drug Facts|
Dapagliflozin/saxagliptin, sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin and saxagliptin. It is taken by mouth.
The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).
In the European Union it is indicated in adults aged 18 years and older with type 2 diabetes mellitus:
- to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control.
- when already being treated with saxagliptin and dapagliflozin.
- "Dapagliflozin / saxagliptin (Qtern) Use During Pregnancy". Drugs.com. 28 June 2019. Retrieved 14 July 2020.
- "Qtern- dapagliflozin and saxagliptin tablet, film coated". DailyMed. 24 January 2020. Retrieved 14 July 2020.
- "Qtern EPAR". European Medicines Agency (EMA). Retrieved 14 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "Drug Approval Package: Qtern (dapagliflozin and saxagliptin)". U.S. Food and Drug Administration (FDA). 10 October 2018. Retrieved 14 July 2020.
- "Dapagliflozin propanediol". Drug Information Portal. U.S. National Library of Medicine.
- "Saxagliptin". Drug Information Portal. U.S. National Library of Medicine.
- "Dapagliflozin". MedlinePlus.
- "Saxagliptin". MedlinePlus.